22/09/2020
Impact on public awareness
RELENT will, with the help of an 
Advisory Board comprised of leading international authorities in science and medicine, together with representatives of Patients’ organisations and experts in Translational Medicine from industry implement a comprehensive strategy of dissemination to reach out to the scientific community, those affected by autoimmune diseases, the stakeholders in Politics and Industry and the general public. RELENTS's Innovation and Exploitation Advisory Panel (IEAP) will regularly review the research programme's results for dissemination to the lay public and generate information material together with the members of the consortium that will be distributed
- on RELENT's dedicated web page,
- through communication to the editors of “
HORIZON: the EU Research & Innovation magazine“, „Horizon2020 projects“ and „HorizonHealth.eu“, - by provide information to Patients’ organisations to be distributed on their web pages (i.e. Working Group Vasculitis and the Vasculitis foundation) and
- by distributing information on dedicated social medias, like LinkedIn or Twitter
Therefore, partners of RELENT are actively promoting public awareness of novel research developments in the diagnosis and care of autoimmune diseases that might have a direct impact on patients' treatment.
RELENT Consortium
